Several resistance mechanisms including upregulation of proangiogenic signaling pathways, increased AXL and MET expression (5), inadequate target inhibition, and resistance mediated by the tumor microenvironment or by the action of microRNAs have been reported. The gene discussed is MET; the disease is neoplasm.